Glutaminase-containing microvesicles from HIV-1-infected macrophages and immune-activated microglia induce neurotoxicity

Molecular Neurodegeneration

Jialin C. Zheng¹  Fang Liu²  Yuju Li¹  Runze Zhao²  Zenghan Tong²  Alexander L. Braun²  Yunlong Huang¹  Beiqing Wu² 

[1] Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200025, China;Laboratory of Neuroimmunology and Regenerative Therapy, Departments of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha 68198-5930, NE, USA

关键词: Neurotoxicity;    Microvesicles;    Glutaminase;    Glutamate;    HIV;    HAND;   

Others  :  1231595
DOI  :  10.1186/s13024-015-0058-z

 received in 2015-04-21, accepted in 2015-11-02,  发布年份 2015

【 摘 要 】

Background

HIV-1-infected and/or immune-activated microglia and macrophages are pivotal in the pathogenesis of HIV-1-associated neurocognitive disorders (HAND). Glutaminase, a metabolic enzyme that facilitates glutamate generation, is upregulated and may play a pathogenic role in HAND. Our previous studies have demonstrated that glutaminase is released to the extracellular fluid during HIV-1 infection and neuroinflammation. However, key molecular mechanisms that regulate glutaminase release remain unknown. Recent advances in understanding intercellular trafficking have identified microvesicles (MVs) as a novel means of shedding cellular contents. We posit that during HIV-1 infection and immune activation, microvesicles may mediate glutaminase release, generating excessive and neurotoxic levels of glutamate.

Results

MVs isolated through differential centrifugation from cell-free supernatants of monocyte-derived macrophages (MDM) and BV2 microglia cell lines were first confirmed in electron microscopy and immunoblotting. As expected, we found elevated number of MVs, glutaminase immunoreactivities, as well as glutaminase enzyme activity in the supernatants of HIV-1 infected MDM and lipopolysaccharide (LPS)-activated microglia when compared with controls. The elevated glutaminase was blocked by GW4869, a neutral sphingomyelinase inhibitor known to inhibit MVs release, suggesting a critical role of MVs in mediating glutaminase release. More importantly, MVs from HIV-1-infected MDM and LPS-activated microglia induced significant neuronal injury in rat cortical neuron cultures. The MV neurotoxicity was blocked by a glutaminase inhibitor or GW4869, suggesting that the neurotoxic potential of HIV-1-infected MDM and LPS-activated microglia is dependent on the glutaminase-containing MVs.

Conclusions

These findings support MVs as a potential pathway/mechanism of excessive glutamate generation and neurotoxicity in HAND and therefore MVs may serve as a novel therapeutic target.

【 授权许可】

   
2015 Wu et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Boisse L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin. 2008; 26:799-819.
• [2]Jiang ZG, Piggee C, Heyes MP, Murphy C, Quearry B, Bauer M et al.. Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. J Neuroimmunol. 2001; 117:97-107.
• [3]Schuenke K, Gelman BB. Human microglial cell isolation from adult autopsy brain: brain pH, regional variation, and infection with human immunodeficiency virus type 1. J Neurovirol. 2003; 9:346-357.
• [4]McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A et al.. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol. 2003; 9:205-221.
• [5]Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem. 2009; 108:1343-1359.
• [6]Ryan LA, Cotter RL, Zink WE, Gendelman HE, Zheng J. Macrophages, chemokines and neuronal injury in HIV-1-associated dementia. Cell Mol Biol (Noisy-le-Grand). 2002; 48:137-150.
• [7]Yamamoto C. [Memory, learning and glutamate receptor]. Rinsho Shinkeigaku. 1989; 29:1526-1528.
• [8]Schousboe A, Larsson OM, Frandsen A, Belhage B, Pasantes-Morales H, Krogsgaard-Larsen P. Neuromodulatory actions of glutamate, GABA and taurine: regulatory role of astrocytes. Adv Exp Med Biol. 1991; 296:165-180.
• [9]Ghijsen WE, Leenders AG, Lopes da Silva FH. Regulation of vesicle traffic and neurotransmitter release in isolated nerve terminals. Neurochem Res. 2003; 28:1443-1452.
• [10]Ollenschlager G, Jansen S, Schindler J, Rasokat H, Schrappe-Bacher M, Roth E. Plasma amino acid pattern of patients with HIV infection. Clin Chem. 1988; 34:1787-1789.
• [11]Droge W, Eck HP, Betzler M, Naher H. Elevated plasma glutamate levels in colorectal carcinoma patients and in patients with acquired immunodeficiency syndrome (AIDS). Immunobiology. 1987; 174:473-479.
• [12]Ferrarese C, Aliprandi A, Tremolizzo L, Stanzani L, De Micheli A, Dolara A et al.. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology. 2001; 57:671-675.
• [13]Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T et al.. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol. 2002; 59:923-928.
• [14]Newcomb R, Sun X, Taylor L, Curthoys N, Giffard RG. Increased production of extracellular glutamate by the mitochondrial glutaminase following neuronal death. J Biol Chem. 1997; 272:11276-11282.
• [15]Erdmann NB, Whitney NP, Zheng J. Potentiation of excitotoxicity in HIV-1 associated dementia and the significance of glutaminase. Clin Neurosci Res. 2006; 6:315-328.
• [16]Tian C, Erdmann N, Zhao J, Cao Z, Peng H, Zheng J. HIV-infected macrophages mediate neuronal apoptosis through mitochondrial glutaminase. J Neurochem. 2008; 105:994-1005.
• [17]McCall A, Glaeser BS, Millington W, Wurtman RJ. Monosodium glutamate neurotoxicity, hyperosmolarity, and blood–brain barrier dysfunction. Neurobehav Toxicol. 1979; 1:279-283.
• [18]Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001; 410:988-994.
• [19]Epstein LG, Gelbard HA. HIV-1-induced neuronal injury in the developing brain. J Leukoc Biol. 1999; 65:453-457.
• [20]Nicklas WJ, Zeevalk G, Hyndman A. Interactions between neurons and glia in glutamate/glutamine compartmentation. Biochem Soc Trans. 1987; 15:208-210.
• [21]Ward HK, Thanki CM, Bradford HF. Glutamine and glucose as precursors of transmitter amino acids: ex vivo studies. J Neurochem. 1983; 40:855-860.
• [22]Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995; 15:133-159.
• [23]Holcomb T, Taylor L, Trohkimoinen J, Curthoys NP. Isolation, characterization and expression of a human brain mitochondrial glutaminase cDNA. Brain Res Mol Brain Res. 2000; 76:56-63.
• [24]Gendelman HE, Persidsky Y, Ghorpade A, Limoges J, Stins M, Fiala M et al.. The neuropathogenesis of the AIDS dementia complex. Aids. 1997; 11 Suppl A:S35-45.
• [25]Thangavelu K, Pan CQ, Karlberg T, Balaji G, Uttamchandani M, Suresh V et al.. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A. 2012; 109:7705-7710.
• [26]Cassago A, Ferreira AP, Ferreira IM, Fornezari C, Gomes ER, Greene KS et al.. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci U S A. 2012; 109:1092-1097.
• [27]Elgadi KM, Meguid RA, Qian M, Souba WW, Abcouwer SF. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics. 1999; 1:51-62.
• [28]Erdmann N, Tian C, Huang Y, Zhao J, Herek S, Curthoys N et al.. In vitro glutaminase regulation and mechanisms of glutamate generation in HIV-1-infected macrophage. J Neurochem. 2009; 109:551-561.
• [29]Huang Y, Zhao L, Jia B, Wu L, Li Y, Curthoys N et al.. Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1-associated neurocognitive disorders. J Neurosci. 2011; 31:15195-15204.
• [30]Ye L, Huang Y, Zhao L, Li Y, Sun L, Zhou Y et al.. IL-1beta and TNF-alpha induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase. J Neurochem. 2013; 125:897-908.
• [31]Zhao J, Lopez AL, Erichsen D, Herek S, Cotter RL, Curthoys NP et al.. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia. J Neurochem. 2004; 88:169-180.
• [32]Tian C, Sun L, Jia B, Ma K, Curthoys N, Ding J et al.. Mitochondrial glutaminase release contributes to glutamate-mediated neurotoxicity during human immunodeficiency virus-1 infection. J Neuroimmune Pharmacol. 2012; 7:619-628.
• [33]Kadiu I, Narayanasamy P, Dash PK, Zhang W, Gendelman HE. Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol. 2012; 189:744-754.
• [34]Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009; 19:43-51.
• [35]Darios F, Wasser C, Shakirzyanova A, Giniatullin A, Goodman K, Munoz-Bravo JL et al.. Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis. Neuron. 2009; 62:683-694.
• [36]Li B, Antonyak MA, Zhang J, Cerione RA. RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells. Oncogene. 2012; 31:4740-4749.
• [37]van der Vos KE, Balaj L, Skog J, Breakefield XO. Brain tumor microvesicles: insights into intercellular communication in the nervous system. Cell Mol Neurobiol. 2011; 31:949-959.
• [38]Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine. 2013; 44:11-19.
• [39]Fais S, Logozzi M, Lugini L, Federici C, Azzarito T, Zarovni N et al.. Exosomes: the ideal nanovectors for biodelivery. Biol Chem. 2013; 394:1-15.
• [40]Fruhbeis C, Frohlich D, Kuo WP, Kramer-Albers EM. Extracellular vesicles as mediators of neuron-glia communication. Front Cell Neurosci. 2013; 7:182.
• [41]Joshi P, Turola E, Ruiz A, Bergami A, Libera DD, Benussi L et al.. Microglia convert aggregated amyloid-beta into neurotoxic forms through the shedding of microvesicles. Cell Death Differ. 2014; 21:582-593.
• [42]Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S et al.. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2012; 287:3842-3849.
• [43]Jayachandran M, Litwiller RD, Lahr BD, Bailey KR, Owen WG, Mulvagh SL et al.. Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res. 2011; 4:811-822.
• [44]Raymond AD, Campbell-Sims TC, Khan M, Lang M, Huang MB, Bond VC et al.. HIV Type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals. AIDS Res Hum Retroviruses. 2011; 27:167-178.
• [45]Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F et al.. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol. 2012; 72:610-624.
• [46]Frleta D, Ochoa CE, Kramer HB, Khan SA, Stacey AR, Borrow P et al.. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest. 2012; 122:4685-4697.
• [47]Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F et al.. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319:1244-1247.
• [48]Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010; 285:17442-17452.
• [49]Zhao L, Huang Y, Tian C, Taylor L, Curthoys N, Wang Y et al.. Interferon-α regulates glutaminase 1 promoter through STAT1 phosphorylation: Relevance to HIV-1 associated neurocognitive disorders. PLoS One. 2012; 7: Article ID e32995
• [50]Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S et al.. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12:1365-71.
• [51]Guo BB, Bellingham SA, Hill AF. The neutral sphingomyelinase pathway regulates packaging of the prion protein into exosomes. The Journal of biological chemistry. 2015; 290:3455-3467.
• [52]Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T et al.. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med. 1988; 167:1428-1441.
• [53]Constantino AA, Huang Y, Zhang H, Wood C, Zheng JC. HIV-1 clade B and C isolates exhibit differential replication: relevance to macrophage-mediated neurotoxicity. Neurotox Res. 2011; 20:277-288.